# US 2024/0067936 A1 · Oncolytic virus and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0067936 A1
- Document ID: US20240067936A1
- Status: Published application
- Kind: A1
- Application number: 18/278,879
- Filed: 2022-02-25
- Published: 2024-02-29
- Earliest claimed: 2021-02-26
- Assignees: Sillajen, Inc.
- Applicants: Sillajen, Inc.
- Inventors: Keunhee OH; Namhee LEE; Byung Jin JUNG; Jun Seung LEE; Kyeong Tae KANG
- Web page: https://patentgrep.com/patent/US20240067936A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 38/1709: {from mammals}
- A61K 38/1725: {Complement proteins, e.g. anaphylatoxin, C3a or C5a}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 35/00: Antineoplastic agents
- C07K 14/07: Vaccinia virus; Variola virus
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/86: Viral vectors
- C12Y 207/01021: Thymidine kinase (2.7.1.21)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C12N 2710/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to an oncolytic virus and the use thereof, specifically, an oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such an oncolytic virus. The oncolytic virus of the present invention maintains its efficacy even when administered intravenously, and thus, it may also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to complement attack by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity when intravenous injection, and thus, it may reduce effective viral dosage to minimize the side effects of anti-cancer drugs.

## Claims

### Claim 1

An oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein.

### Claim 2 (depends on 1)

The oncolytic virus according to claim 1, wherein the suppressed thymidine kinase gene expression is due to deletion of part or all of the gene, or insertion of a foreign gene into the gene.

### Claim 3 (depends on 2)

The oncolytic virus according to claim 2, wherein a foreign gene is inserted into part or all of the thymidine kinase J2R region.

### Claim 4 (depends on 1)

The oncolytic virus according to claim 1, wherein the complement regulatory protein is CD35, CD21, CD18, CD55, CD46, or CD59.

### Claim 5 (depends on 1)

The oncolytic virus according to claim 1, further comprising a gene encoding a transmembrane domain of an oncolytic virus membrane protein.

### Claim 6 (depends on 5)

The oncolytic virus according to claim 5, wherein the gene encoding the transmembrane domain of the oncolytic virus membrane protein is fused with a gene encoding the complement regulatory protein.

### Claim 7 (depends on 5)

The oncolytic virus according to claim 5, wherein the oncolytic virus membrane protein is D8L, A16L, F9L, G9R, H3L, L1R, A9L, A13L, A21L, A28L, E10R, G3L, H2R, I2L, J5L, L5R, or O3L.

### Claim 8 (depends on 1)

The oncolytic virus according to claim 1, wherein the complement regulatory protein is CD55 composed of the sequence of SEQ ID NO: 1.

### Claim 9 (depends on 1)

The oncolytic virus according to claim 1, wherein the GM-CSF and the complement regulatory protein are expressed under the control of a late-early VACV p7.5 promoter, a vaccinia synthetic early-late promoter (pSEL), a vaccinia synthetic late promoter (pSL), a vaccinia modified H5 (mH5) promoter, a vaccinia short synthetic early-late pS promoter, a pLate promoter, a pC11R promoter, a pF11L promoter, a psFJ1-10 synthetic early promoter, a pHyb synthetic early promoter, any natural vaccinia early promoter, or a late-early optimized (LEO) promoter, respectively.

### Claim 10 (depends on 1)

The oncolytic virus according to claim 1, wherein the oncolytic virus is vaccinia virus, adenovirus, herpes simplex virus, retrovirus, reovirus, Newcastle disease virus, coxsackie virus, enterovirus, or herpes virus.

### Claim 11 (depends on 10)

The oncolytic virus according to claim 10, wherein the vaccinia virus is Western Reserve (WR), New York vaccinia virus (NYVAC), Wyeth, LC16m8, Lister, Copenhagen, Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J), or International Health Division-White (IHD-W) strain.

### Claim 12 (depends on 1)

A pharmaceutical composition, comprising the oncolytic virus according to claim 1 as an active ingredient.

### Claim at position 13

13-15. (canceled)

### Claim 16 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the composition is for intratumoral, intravascular, intramuscular or intraperitoneal administration.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the composition is for intravenous or arterial administration.

### Claim 18

A genetic construct for insertion into an oncolytic virus, comprising all or part of a gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), a gene encoding a transmembrane domain of a vaccinia virus membrane protein and a gene encoding a complement regulatory protein, and operably linked to an early-late promoter and a late promoter for expression.

### Claim 19 (depends on 18)

The genetic construct according to claim 18, wherein the genetic construct is for insertion into an inactivated thymidine kinase gene region of the oncolytic virus.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

An anti-cancer adjuvant comprising the oncolytic virus according to claim 1 as an active ingredient.

### Claim 22 (depends on 1)

A method of preventing or treating cancer, comprising;
administering to a subject in need thereof a composition comprising the oncolytic virus according to claim 1 as an active ingredient.

### Claim at position 21

23-24. (canceled)

### Claim 25 (depends on 22)

The method according to claim 22, wherein the cancer is solid cancer or hematologic malignancy,
wherein the solid cancer is any one selected from the group consisting of lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymus cancer, stomach cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, renal cancer, osteosarcoma, sarcoma, chondrosarcoma, and combinations thereof, and
wherein the hematologic malignancy is any one selected from the group consisting of lymphoma, leukemia, multiple myeloma, and combinations thereof.

### Claim 26 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the suppressed thymidine kinase gene expression is due to deletion of part or all of the gene, or insertion of a foreign gene into the gene.

### Claim 27 (depends on 16)

The pharmaceutical composition according to claim 16, wherein a foreign gene is inserted into part or all of the thymidine kinase J2R region.

### Claim 28 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the complement regulatory protein is CD35, CD21, CD18, CD55, CD46, or CD59.

### Claim 29 (depends on 12)

The pharmaceutical composition according to claim 12, further comprising a gene encoding a transmembrane domain of an oncolytic virus membrane protein.

### Claim 30 (depends on 29)

The pharmaceutical composition according to claim 29, wherein the gene encoding the transmembrane domain of the oncolytic virus membrane protein is fused with a gene encoding the complement regulatory protein.

### Claim 31 (depends on 29)

The pharmaceutical composition according to claim 29, wherein the oncolytic virus membrane protein is D8L, A16L, F9L, G9R, H3L, L1R, A9L, A13L, A21L, A28L, E10R, G3L, H2R, I2L, J5L, L5R, or O3L.

### Claim 32 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the complement regulatory protein is CD55 composed of the sequence of SEQ ID NO: 1.

### Claim 33 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the GM-CSF and the complement regulatory protein are expressed under the control of a late-early VACV p7.5 promoter, a vaccinia synthetic early-late promoter (pSEL), a vaccinia synthetic late promoter (pSL), a vaccinia modified H5 (mH5) promoter, a vaccinia short synthetic early-late pS promoter, a pLate promoter, a pC11R promoter, a pF11L promoter, a psFJ1-10 synthetic early promoter, a pHyb synthetic early promoter, any natural vaccinia early promoter, or a late-early optimized (LEO) promoter, respectively.

### Claim 34 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the oncolytic virus is vaccinia virus, adenovirus, herpes simplex virus, retrovirus, reovirus, Newcastle disease virus, coxsackie virus, enterovirus, or herpes virus.

### Claim 35 (depends on 34)

The pharmaceutical composition according to claim 34, wherein the vaccinia virus is Western Reserve (WR), New York vaccinia virus (NYVAC), Wyeth, LC16m8, Lister, Copenhagen, Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J), or International Health Division-White (IHD-W) strain.

### Claim 36 (depends on 21)

The anti-cancer adjuvant according to claim 21, wherein the suppressed thymidine kinase gene expression is due to deletion of part or all of the gene, or insertion of a foreign gene into the gene.

### Claim 37 (depends on 26)

The anti-cancer adjuvant according to claim 26, wherein a foreign gene is inserted into part or all of the thymidine kinase J2R region.

### Claim 38 (depends on 21)

The anti-cancer adjuvant according to claim 21, wherein the complement regulatory protein is CD35, CD21, CD18, CD55, CD46, or CD59.

### Claim 39 (depends on 21)

The anti-cancer adjuvant according to claim 21, further comprising a gene encoding a transmembrane domain of an oncolytic virus membrane protein.

### Claim 40 (depends on 39)

The anti-cancer adjuvant according to claim 39, wherein the gene encoding the transmembrane domain of the oncolytic virus membrane protein is fused with a gene encoding the complement regulatory protein.

### Claim 41 (depends on 39)

The anti-cancer adjuvant according to claim 39, wherein the oncolytic virus membrane protein is D8L, A16L, F9L, G9R, H3L, L1R, A9L, A13L, A21L, A28L, E10R, G3L, H2R, I2L, J5L, L5R, or O3L.

### Claim 42 (depends on 21)

The anti-cancer adjuvant according to claim 21, wherein the complement regulatory protein is CD55 composed of the sequence of SEQ ID NO: 1.

### Claim 43 (depends on 21)

The anti-cancer adjuvant according to claim 21, wherein the GM-CSF and the complement regulatory protein are expressed under the control of a late-early VACV p7.5 promoter, a vaccinia synthetic early-late promoter (pSEL), a vaccinia synthetic late promoter (pSL), a vaccinia modified H5 (mH5) promoter, a vaccinia short synthetic early-late pS promoter, a pLate promoter, a pC11R promoter, a pF11L promoter, a psFJ1-10 synthetic early promoter, a pHyb synthetic early promoter, any natural vaccinia early promoter, or a late-early optimized (LEO) promoter, respectively.

### Claim 44 (depends on 21)

The anti-cancer adjuvant according to claim 21, wherein the oncolytic virus is vaccinia virus, adenovirus, herpes simplex virus, retrovirus, reovirus, Newcastle disease virus, coxsackie virus, enterovirus, or herpes virus.

### Claim 45 (depends on 44)

The anti-cancer adjuvant according to claim 44, wherein the vaccinia virus is Western Reserve (WR), New York vaccinia virus (NYVAC), Wyeth, LC16m8, Lister, Copenhagen, Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J), or International Health Division-White (IHD-W) strain.

### Claim 46 (depends on 22)

The method according to claim 22, wherein the suppressed thymidine kinase gene expression is due to deletion of part or all of the gene, or insertion of a foreign gene into the gene.

### Claim 47 (depends on 46)

The method according to claim 46, wherein a foreign gene is inserted into part or all of the thymidine kinase J2R region.

### Claim 48 (depends on 22)

The method according to claim 22, wherein the complement regulatory protein is CD35, CD21, CD18, CD55, CD46, or CD59.

### Claim 49 (depends on 22)

The method according to claim 22, further comprising a gene encoding a transmembrane domain of an oncolytic virus membrane protein.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the gene encoding the transmembrane domain of the oncolytic virus membrane protein is fused with a gene encoding the complement regulatory protein.

### Claim 51 (depends on 49)

The method according to claim 49, wherein the oncolytic virus membrane protein is D8L, A16L, F9L, G9R, H3L, L1R, A9L, A13L, A21L, A28L, E10R, G3L, H2R, I2L, J5L, L5R, or O3L.

### Claim 52 (depends on 22)

The method according to claim 22, wherein the complement regulatory protein is CD55 composed of the sequence of SEQ ID NO: 1.

### Claim 53 (depends on 22)

The method according to claim 22, wherein the GM-CSF and the complement regulatory protein are expressed under the control of a late-early VACV p7.5 promoter, a vaccinia synthetic early-late promoter (pSEL), a vaccinia synthetic late promoter (pSL), a vaccinia modified H5 (mH5) promoter, a vaccinia short synthetic early-late pS promoter, a pLate promoter, a pC11R promoter, a pF11L promoter, a psFJ1-10 synthetic early promoter, a pHyb synthetic early promoter, any natural vaccinia early promoter, or a late-early optimized (LEO) promoter, respectively.

### Claim 54 (depends on 22)

The method according to claim 22, wherein the oncolytic virus is vaccinia virus, adenovirus, herpes simplex virus, retrovirus, reovirus, Newcastle disease virus, coxsackie virus, enterovirus, or herpes virus.

### Claim 55 (depends on 54)

The method according to claim 54, wherein the vaccinia virus is Western Reserve (WR), New York vaccinia virus (NYVAC), Wyeth, LC16m8, Lister, Copenhagen, Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J), or International Health Division-White (IHD-W) strain.
